Diagnosis, Staging and Treatment of Patients with Breast Cancer

Objectives

National Clinical Guideline No. 7 is Ireland’s evidence-based framework for improving the quality, safety, consistency and cost-effectiveness of diagnosis, staging and treatment for adults with newly diagnosed early or locally advanced breast cancer. It supports the National Cancer Control Programme’s wider aims to improve cancer outcomes, survival and quality of life through translation of research and surveillance into clinical practice.[1][2][3][4]

• Improve clinical decision-making, patient outcomes and quality of life, while reducing morbidity and mortality where possible.[2]
• Reduce unwarranted variation in breast cancer care by applying research evidence, clinical expertise and an internationally recognised evidence-based methodology.[2][3]
• Cover the patient pathway from early detection and diagnosis through staging, surgery, systemic therapy, radiotherapy, monitoring, survivorship, palliative care and end-of-life care.[1][5][6]
• Focus on patients aged 18 years or over with newly diagnosed early or locally advanced breast cancer, excluding screening, metastatic and recurrent breast cancer.[3][4]
• Prioritise clinical questions where practice variation, uncertainty, controversy, emerging evidence or potential impact on care is greatest.[3][7]
• Promote appropriate diagnostic assessment, including triple assessment, selective magnetic resonance imaging, axillary ultrasound and risk-stratified staging, while avoiding low-value routine imaging in asymptomatic early-stage disease.[8][9][10][11]
• Support informed treatment choices between breast-conserving surgery with radiotherapy and mastectomy, with reconstruction discussions for all patients undergoing mastectomy and proportionate axillary management.[12][13][14][15]
• Provide risk-adapted systemic therapy, including chemotherapy, endocrine therapy, trastuzumab for eligible human epidermal growth factor receptor 2-positive disease, neoadjuvant treatment and combined-modality care for inflammatory breast cancer.[16][17][18][19][20]
• Deliver radiotherapy according to recurrence risk and surgical treatment, including hypofractionated schedules for early breast cancer and appropriate postmastectomy and regional nodal irradiation.[21][22][23][24]
• Introduce palliative care early, reassess needs throughout illness and provide support at the level of expertise required by each patient and family.[5][6]

Implementation

The guideline is developed, disseminated and implemented through the National Cancer Control Programme within the Health Service Executive, using multidisciplinary governance, structured evidence appraisal, behaviour-change methods, hospital-level accountability and audit. Care is intended to be delivered by multidisciplinary clinical teams across designated cancer centres and breast units, with shared decision-making involving patients and, where appropriate, families.[1][2][4][25][26]

• Govern development through a National Cancer Control Programme Guideline Steering Group chaired by the Programme Director and a multidisciplinary Guideline Development Group comprising relevant clinical specialists, a project manager, methodologist and clinical librarians.[4]
• Apply Evidence-Based Practice principles, formulate clinical questions using the Population, Intervention, Comparator, Outcome and Time framework, search guideline and primary-literature databases, and appraise evidence using recognised tools.[7][27][28][29][30]
• Formulate recommendations through evidence tables and structured judgement of evidence quality, consistency, applicability to Ireland, benefits, harms, health-system impact and resource implications.[27]
• Engage patients, advocacy organisations, professional groups, national stakeholders and international experts through the Health Service Executive Patient Forum, stakeholder review and documented consultation processes.[27][31][32]
• Assign corporate responsibility for implementation to hospital Chief Executive Officers, General Managers and Clinical Directors, while making individual multidisciplinary team members responsible for recommendations relevant to their disciplines.[4][26][33]
• Nominate a breast cancer lead clinician in each designated Breast Unit and support performance monitoring and service planning through quarterly meetings between the National Cancer Control Programme Cancer Network Manager and cancer-centre leadership.[25][31][34]
• Use the Capability, Opportunity, Motivation and Behaviour model and the Behaviour Change Wheel to identify barriers and facilitators, match recommendations to education, training, enablement and other intervention functions, and distinguish changes from current practice.[35]
• Disseminate the guideline through professional networks and National Cancer Control Programme and National Clinical Effectiveness Committee websites, supported by general practitioner referral guidance, electronic referral, clinical protocols, patient information, survivorship materials and quality-assurance resources.[3][25][36]
• Provide service capacity where required, including access to magnetic resonance imaging, training and equipment for magnetic resonance-guided biopsy, while seeking additional implementation resources through the Health Service Executive service-planning process.[37][38][39]
• Audit implementation and patient outcomes using specified clinical criteria and data definitions, including indicators for axillary ultrasound, breast-conserving surgery activity and radiotherapy commencing within 12 weeks of final therapeutic surgery.[25][36][40]
• Use National Cancer Registry of Ireland data where available to monitor survival by stage and tumour type, surgical treatment patterns, axillary management and residual tumour after treatment.[40]
• Review the literature periodically, consider the guideline for review three years after publication, record approved updates on National Cancer Control Programme and National Clinical Effectiveness Committee websites, and update recommendations as new evidence emerges.[25][6]

Monitoring & Evaluation

The guideline establishes a multi-level monitoring and accountability approach, combining national oversight, hospital-level responsibility, multidisciplinary team delivery, clinical audit, performance monitoring and scheduled evidence review. The National Clinical Effectiveness Committee provides quality assurance for national clinical guidelines and clinical audit, and reports periodically on guideline implementation, impact and audit performance.[1]Corporate accountability rests with hospital Chief Executive Officers, General Managers and Clinical Directors, while multidisciplinary team members are responsible for discipline-specific recommendations.[4][26]

• Develop and agree Key Performance Indicators through the Breast National Clinical Leads Network.[3]
• Conduct annual multidisciplinary Cancer Quality and Audit Fora to address cancer-specific quality issues.[3]
• Audit implementation and patient outcomes using the criteria specified in appendix 10.[25]
• Monitor cancer-centre performance and service planning through quarterly meetings between the National Cancer Control Programme Cancer Network Manager and each cancer centre’s Chief Executive Officer or General Manager.[25][31]
• Review the guideline through periodic surveillance of the literature, with review scheduled three years after its June 2015 publication; record approved updates on the National Cancer Control Programme and National Clinical Effectiveness Committee websites.[25]
• Maintain logs of stakeholder and international expert review submissions and resulting amendments.[27][25]
• Document evidence searches, appraisal judgements, recommendation grades, considered-judgement decisions and supporting amendments during guideline development.[7][27]

Specified audit indicators cover axillary ultrasound for patients undergoing defined breast-cancer operations, surgical activity and re-excision following breast-conserving surgery, and commencement of radiotherapy alone within 12 weeks, or 84 days, of the final therapeutic operation.[36][40]National Cancer Registry of Ireland data may be used to monitor survival by stage and tumour type, surgical treatment patterns, axillary management and residual tumour after treatment.[40]Clinical monitoring also includes cardiac-function assessment for patients receiving anthracyclines or trastuzumab.[16]The source does not provide complete indicator definitions, targets, reporting templates, routine surveillance methods or evaluation findings for all recommendations.[3][36][40]

Costing & Financing

The guideline was commissioned and funded by the National Cancer Control Programme, and additional resources required for recommendations are to be sought through the Health Service Executive service-planning process.[4][25][39]Many recommendations are considered cost neutral because they reflect existing standard practice, although changes in service delivery may have resource implications.[25]

• Undertake budget-impact assessment for recommendations that affect resource requirements and consider resource implications and health-system impact when formulating recommendations.[7][27][39]
• Assess economic evidence using studies whose populations, costs and treatments are sufficiently similar to Ireland, with appraisal by a health economist.[39]
• Adjust international euro estimates for exchange rates, purchasing power parity and health inflation to 2013, while recognising that international findings may not transfer directly to Ireland.[41]
• Apply no explicit Irish cost-effectiveness threshold for non-drug interventions; ratios of €20,000 to €45,000 per quality-adjusted life year are conventionally regarded as cost-effective.[41]
• Recognise that shorter radiotherapy fractionation may reduce radiotherapy usage by up to 30%, while enforcing a treatment interval under 12 weeks could have significant resource implications without demonstrated benefit.[42]

Economic evidence identifies substantial cancer-related expenditure in Ireland and the European Union, alongside potential savings from reducing unnecessary staging investigations in stage I and II breast cancer.[41][43]Palliative care was frequently less costly than comparator care in a 2013 literature review.[5]The document does not specify a total implementation budget, dedicated funding allocation, financing gap or comprehensive resource-mobilisation plan.[25][39]